NK Vue®
The Principle of NK VUE Diagnosis
NK VUE artificially activates the NK cells in the blood using our patented NK Cell activator (Promoca) and measures the amount of Interferon gamma secreted using the method of enzyme-linked immunosorbent assay (ELISA).
- Step1. Draw blood (1ml)
- Step2. NK cells incubation (37°C, 20~24 hours)
- Step3. IFN-γ secretion
- Step4. Supernatant collected.
- Step5. ELISA tested
- Step6. Results verified
What is NK cell activity test?
This test measures the amount of Interferon gamma (IFN-γ) secreted after artificially activating NK cells in the blood.
It can help evaluate your body’s natural immunity against cancer or other diseases.
- Difference in NK Cell Activity between Cancer Patients and Healthy People
- There is a significant difference in NK cell activity between cancer patients and healthy people.
- Difference in NK Cell Activity by age or sex
- There is no significant difference in NK cell activity depending on age or sex.
Clinical trial: 2011-2012, Yonsei University Severance Hospital Clinical Test Center
Comparison of NK VUE with conventional methods
NK VUE is much simpler to use compared to the conventional NK cell activity tests.
| Conventional methods | NK Vue® method | |||
|---|---|---|---|---|
| Flow cytometric Assay | Chromium-51 Release Assay | Flow cytometric Assay (CD107a degranulation assay) |
NK Vue® Kit | |
| Object | NK cell number counting | NK cell cytotoxicity | NK cell cytotoxicity | NK cell activity |
| Marker | CD3, CD16/56 | 51Cr (radioisotope) | CD3, CD16/56, CD107a | IFN-γ |
| Blood collection | 2mL | Variable depends on NK cell number | Variable depends on NK cell number | 1mL |
| Sample Type | PBMC | PBMC or lymphocytes | PBMC | Whole blood |
| Disadvantage | Only the relative percentage (%) of NK cells can be measured |
-Using radioisotope -Complicated experiments & low reproducibility -Expensive and time consuming |
Sensitivity and reproducibility may vary depending on the number of cells | - |
Potential Application of NK Cell Activity Test in Various Areas
-
Pre-
screening- Screening prior to PET-CT and CT examination
- For biopsy pre-examination
- Early detection of recurrence
- Colorectal cancer pre-screening
- Gastroenterology Journal in June 2017 (Canada)
- JGH Journal in October 2017 (Korea)
-
Immunity
Benchmark- Complement general health test such as DNA test, Antioxidant test, Biometric Age test
- Regular health check-up
- Hospital Health Center and Korea Medical Institutions
- Korean Industrial Health Association and Korea Association of Health Promotions
-
Complementary
Diagnosis- Tested with tumor marker tests
- Sensitivity and specificity improvement
- Prostate cancer
- Can J Urol Journal in April 2017 (Canada)
- Gastric cancer
- Oncotarget Journal July 2017 (Korea)
-
Treatment
Monitoring- Predicting effects on various drugs and treatments
- Monitoring after chemotherapy
- Monitoring Pre-chemotherapy treatment
- ESMO Poster (European Society for Medical Oncology) in September 2017 (Spain)
- ASCO Poster in June 2018 (U.S.A)
The following conditions or drugs have been known to temporarily affect immune cell function and significantly influence the test results:
Viral or bacterial infection / Autoimmune diseases. / Immunosuppressive drugs. / Acute Stress or Severe fatigue Sleep Disorders / Steroid-based drugs